Literature DB >> 17478473

Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency.

G Jönsson1, A G Sjöholm, L Truedsson, A A Bengtsson, J H Braconier, G Sturfelt.   

Abstract

OBJECTIVE: To analyse rheumatological manifestations, organ damage and autoimmune responses in a large cohort of patients (n = 45) with homozygous C2 deficiency (C2D) and long-term follow-up.
METHODS: Medical records were reviewed and were supplemented with a mailed questionnaire for assessment of cardiovascular disease (CVD) risk factors. Organ damage was evaluated using the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI). Causes for disability pensions were investigated. Autoantibodies were determined with established methods.
RESULTS: Patients with rheumatological diseases had systemic lupus erythematosus (SLE, n = 12), undifferentiated connective tissue disease (n = 5) or vasculitis (n = 3). Judging from annual SLICC/ACR DI, C2D patients with SLE run a similar risk of development of severe disease as other patients with SLE. An increased rate of CVD was observed not explained by Framingham-related risk factors. Disability pensions were mainly related to rheumatological disease. The prevalence of anti-nuclear antibodies in C2D with SLE and of anti-SS-A was 25% while anti-RNP was found in 45%. Only one patient showed antibodies to dsDNA. Formation of anti-cardiolipin antibodies (aCL) appeared to be increased in C2D despite the absence of an anti-phospholipid syndrome. The prevalence of antibodies to the collagen-like region of C1q (C1qCLR) was also remarkably high and was not related to rheumatological manifestations.
CONCLUSIONS: Severity of SLE in C2D is similar to that of SLE in other patients. Conventional risk factors do not explain the occurrence of CVD in C2D. The high prevalence of aCL and anti-C1qCLR indicates mechanisms through which impaired complement function promotes formation of autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478473     DOI: 10.1093/rheumatology/kem023

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  20 in total

Review 1.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 2.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

Review 3.  The yin and the yang of early classical pathway complement disorders.

Authors:  Kathleen E Sullivan
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 4.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 5.  Complement deficiencies in systemic lupus erythematosus.

Authors:  Angela R Bryan; Eveline Y Wu
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

Review 6.  Monogenic systemic lupus erythematosus: insights in pathophysiology.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-05-15       Impact factor: 2.631

Review 7.  Autoimmunity and Immune Dysregulation in Primary Immune Deficiency Disorders.

Authors:  Heather K Lehman
Journal:  Curr Allergy Asthma Rep       Date:  2015-09       Impact factor: 4.806

8.  Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.

Authors:  Christian Lood; Helena Tydén; Birgitta Gullstrand; Gunnar Sturfelt; Andreas Jönsen; Lennart Truedsson; Anders A Bengtsson
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

9.  Anti-C1q antibodies in systemic lupus erythematosus.

Authors:  A-M Orbai; L Truedsson; G Sturfelt; O Nived; H Fang; G S Alarcón; C Gordon; Jt Merrill; P R Fortin; I N Bruce; D A Isenberg; D J Wallace; R Ramsey-Goldman; S-C Bae; J G Hanly; J Sanchez-Guerrero; A E Clarke; C B Aranow; S Manzi; M B Urowitz; D D Gladman; K C Kalunian; M I Costner; V P Werth; A Zoma; S Bernatsky; G Ruiz-Irastorza; M A Khamashta; S Jacobsen; J P Buyon; P Maddison; M A Dooley; R F Van Vollenhoven; E Ginzler; T Stoll; C Peschken; J L Jorizzo; J P Callen; S S Lim; B J Fessler; M Inanc; D L Kamen; A Rahman; K Steinsson; A G Franks; L Sigler; S Hameed; N Pham; R Brey; M H Weisman; G McGwin; L S Magder; M Petri
Journal:  Lupus       Date:  2014-08-14       Impact factor: 2.911

10.  Bacteria in the adventitia of cardiovascular disease patients with and without rheumatoid arthritis.

Authors:  Samuel A Curran; Ivana Hollan; Clett Erridge; David F Lappin; Colin A Murray; Gunnar Sturfelt; Knut Mikkelsen; Oystein T Førre; Sven M Almdahl; Magne K Fagerhol; Carl S Goodyear; Marcello P Riggio
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.